Compound useful for the treatment of degenerative and inflammatory diseases
A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
1. A method for the treatment of ulcerative colitis, comprising administering an amount of a compound according to Formula I:
or pharmaceutically acceptable salt thereof, sufficient to effect said treatment.
2. The method according to claim 1 , wherein the compound or pharmaceutically acceptable salt thereof, is administered in combination with a further therapeutic agent for the treatment of ulcerative colitis.
3. A method for the treatment of ulcerative colitis, comprising administering an amount of the pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment.
4. The method according to claim 3 , wherein said compound is administered in combination with one or more further therapeutic agents selected from ulcerative colitis treatment agents.
5. The method according to claim 3 , wherein said compound is administered in combination with one further therapeutic agent selected from ulcerative colitis treatment agents.
6. The method according to claim 2 , wherein the further therapeutic agent is an agent selected from glucocorticoids, synthetic disease modifying immunomodulatory agents, and biological disease modifying immunomodulatory agents.
7. The method according to claim 4 , wherein the further therapeutic agent is an agent selected from glucocorticoids, synthetic disease modifying immunomodulatory agents, and biological disease modifying immunomodulatory agents.
8. The method according to claim 5 , wherein the further therapeutic agent is an agent selected from glucocorticoids, synthetic disease modifying immunomodulatory agents, and biological disease modifying immunomodulatory agents.
9. The method according to claim 6 , wherein the further therapeutic agent is an agent selected from prednisone, budesonide, methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin, infliximab, adalimumab, rituximab, and abatacept.
10. The method according to claim 7 , wherein the further therapeutic agent is an agent selected from prednisone, budesonide, methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin, infliximab, adalimumab, rituximab, and abatacept.
11. The method according to claim 8 , wherein the further therapeutic agent is an agent selected from prednisone, budesonide, methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin, infliximab, adalimumab, rituximab, and abatacept.